» Articles » PMID: 19501407

Development and Progression of Diabetic Retinopathy 12 Months After Phacoemulsification Cataract Surgery

Overview
Journal Ophthalmology
Publisher Elsevier
Specialty Ophthalmology
Date 2009 Jun 9
PMID 19501407
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess whether phacoemulsification cataract surgery exacerbates the development and progression of diabetic retinopathy (DR) in a cataract surgical cohort.

Design: Clinic-based cohort study.

Participants: Patients aged 65+ years undergoing cataract surgery at an eye clinic in Sydney, Australia, between 2004 and 2006.

Methods: Digital retinal photography was performed after pupil dilation preoperatively and at 1-, 6-, and 12-month postoperative visits. DR was assessed using the modified Early Treatment Diabetic Retinopathy Study (ETDRS) classification. Preoperative and 1-month postoperative (baseline) photographs were compared side-by-side with 12-month postoperative photographs. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for DR progression in operated (pseudophakic) compared with nonoperated (phakic) eyes, adjusted for age, sex, diabetes duration, and preoperative glycosylated hemoglobin level.

Main Outcome Measures: Incident DR was defined in eyes without DR at baseline in which DR was detected at 12-month postoperative visits. DR progression was defined as an increase of 1 or more ETDRS steps during the same period, including incident cases.

Results: Of 1994 surgical patients recruited, 190 (9.53%) with diabetes and complete data and thus were included. There were 56 patients with unilateral surgery performed before baseline (mean postoperative duration 3.3+/-3.3 years). The prevalence of DR at baseline was higher in these 56 pseudophakic eyes than in 324 phakic eyes (71.4% vs. 48.2%, respectively, adjusted OR 2.16; 95% CI, 1.16-4.03). Of the 190 patients, 169 were followed for 12+ months postoperatively; 278 eyes were pseudophakic, and 60 eyes remained phakic at 12 months. During the 12-month postoperative period, incident DR developed in 28.2% of pseudophakic eyes and 13.8% of phakic eyes (adjusted OR 2.65; 95% CI, 1.06-6.61). In a paired-eye comparison of 45 patients who remained unilaterally pseudophakic at 12 months and were at risk of DR progression, 35.6% of pseudophakic eyes exhibited DR progression compared with 20.0% of the fellow phakic eyes (adjusted OR 2.21; 95% CI, 0.85-5.71).

Conclusions: Diabetic patients undergoing phacoemulsification cataract surgery appear to have a doubling of DR progression rates 12 months after surgery. This outcome, however, represents less progression than was previously documented with intracapsular and extracapsular cataract surgical techniques.

Citing Articles

The Role of Immune Cells and Signaling Pathways in Diabetic Eye Disease: A Comprehensive Review.

Barone V, Surico P, Cutrupi F, Mori T, Gallo Afflitto G, Di Zazzo A Biomedicines. 2024; 12(10).

PMID: 39457658 PMC: 11505591. DOI: 10.3390/biomedicines12102346.


Alterations in optical coherence tomography angiography parameters after cataract surgery in patients with diabetes.

Kim J, Kim S, Borrelli E, Park M, Cho B, Kwon S Sci Rep. 2024; 14(1):23814.

PMID: 39394214 PMC: 11469999. DOI: 10.1038/s41598-024-73830-w.


Distance and near vision changes after intravitreal anti-vascular endothelial growth factor injection in eyes with center-involving diabetic macular edema.

Rajasekar L, Kashyap H, Nadig R, Jaisankar D, Sathyaprasath M, Laxmi G Indian J Ophthalmol. 2023; 71(7):2796-2802.

PMID: 37417123 PMC: 10491087. DOI: 10.4103/ijo.IJO_1949_22.


Comparison of the Effectiveness of Intravitreal Bevacizumab Injections with and without Simultaneous Cataract Surgery in Diabetic Patients with Macular Edema.

Kwak J, Lee Y, Kang K, Kim Y J Clin Med. 2023; 12(12).

PMID: 37373753 PMC: 10299508. DOI: 10.3390/jcm12124060.


Implementing a Diabetic Algorithm for Ophthalmology Surgery Patients: A Quality Improvement Initiative.

Sandhu S, Virani A, Salmonson H, Damji K, Mathura P, Al-Agha R Glob J Qual Saf Healthc. 2023; 5(4):93-99.

PMID: 37260931 PMC: 10229036. DOI: 10.36401/JQSH-21-18.